Our 2025 Database of Anti-B7-H3/B7-H4 Therapeutic Programmes in oncology is available for free download here.
🔬 What’s inside?
✅ 17 Antibody-drug conjugate (ADC) programmes
✅ 11 Bispecifics & 2 monoclonal antibodies (mAbs) targeting B7-H3 or B7-H4
✅ 6 CART-T & CAR-NK programmes
✅ 1 radiotherapy (RT) programme (Phase II) based on an anti-B7-H3 mAb
Featuring anti-B7-H3/B7-H4 programmes from leading players, including:
ABL Bio, Amgen, Anhui Anke Biotechnology, AstraZeneca, BioNTech, Bio-Thera Solutions, Biocytogen, Cullinan Oncology, Daiichi Sankyo, Dartsbio Pharmaceuticals, DualityBio, Five Prime, GSK, Hansoh Pharma, Harbour BioMed, Iksuda Therapeutics, LigaChem Biosciences, Mabstone Biotechnologies, MacroGenics, Maverick Therapeutics, MediLink Therapeutics, Memorial Sloan Kettering Cancer Center, Merck, Mersana Therapeutics, Minghui Pharmaceutical, NextCure, Pfizer, Seagen, Synaffix, lonza, Takeda, Xencor, Y‑mAbs Therapeutics - and more!
🔬 What’s inside?
✅ 17 Antibody-drug conjugate (ADC) programmes
✅ 11 Bispecifics & 2 monoclonal antibodies (mAbs) targeting B7-H3 or B7-H4
✅ 6 CART-T & CAR-NK programmes
✅ 1 radiotherapy (RT) programme (Phase II) based on an anti-B7-H3 mAb
Featuring anti-B7-H3/B7-H4 programmes from leading players, including:
ABL Bio, Amgen, Anhui Anke Biotechnology, AstraZeneca, BioNTech, Bio-Thera Solutions, Biocytogen, Cullinan Oncology, Daiichi Sankyo, Dartsbio Pharmaceuticals, DualityBio, Five Prime, GSK, Hansoh Pharma, Harbour BioMed, Iksuda Therapeutics, LigaChem Biosciences, Mabstone Biotechnologies, MacroGenics, Maverick Therapeutics, MediLink Therapeutics, Memorial Sloan Kettering Cancer Center, Merck, Mersana Therapeutics, Minghui Pharmaceutical, NextCure, Pfizer, Seagen, Synaffix, lonza, Takeda, Xencor, Y‑mAbs Therapeutics - and more!